Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2022 Earnings Call Transcript

LCTX earnings call for the period ending March 31, 2022.

LCTX : 1.2500 (unch)
Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of -500% and 56.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LCTX : 1.2500 (unch)
NXGN : 17.90 (+1.24%)
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating...

LCTX : 1.2500 (unch)
BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BCDA : 1.5500 (-8.28%)
LCTX : 1.2500 (unch)
Urogen Pharma (URGN) Reports Q1 Loss, Misses Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of 8.09% and 13.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

URGN : 5.15 (-6.53%)
LCTX : 1.2500 (unch)
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -24.43% and 5.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

RARE : 45.80 (-4.46%)
LCTX : 1.2500 (unch)
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report...

LCTX : 1.2500 (unch)
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from the...

LCTX : 1.2500 (unch)
Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today Brian M. Culley, Lineage’s...

LCTX : 1.2500 (unch)
Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced a new cell therapy...

LCTX : 1.2500 (unch)

Barchart Exclusives

2 Covered Call Ideas on Johnson & Johnson Stock
With markets looking increasingly volatile, investors might be more interested in generating income rather than capital gains. Johnson & Johnson (JNJ) is a solid defensive play that has held up well so far this year. JNJ also pays a healthy dividend with the current dividend yield sitting at 2.40%. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar